Loading

Journal of Veterinary Medicine and Research

Age-Dependent Change of Hepatic Flavin Containing Monooxygenase and Aldehyde Oxidase Activities in Chickens

Research Article | Open Access

  • 1. Veterinary Medicine Research and Development, USA
+ Show More - Show Less
Corresponding Authors
Steven X Hu, Veterinary Medicine Research and Development, Zoetis, Inc., USA, 333 Portage Street, Kalamazoo, Michigan, USA; Fax: 1-269-290-7868; Tel: 1-269-359-9239
ABSTRACT

Flavin containing monooxygenases (FMO) and aldehyde oxidases (AO) are two important groups of non-cytochrome P450 enzymes in animals and humans. Age-dependent hepatic activities of those enzymes were evaluated in male Ross 708 broiler chickensat age 1, 7, 14, 28 and 56 days. FMO activity was significantly higher in chicken livers at age of day 1, declined rapidly to the lowest level measured at age of day 14 and then gradually increased. Meanwhile hepatic AO was low in chicken at age of day 1 and gradually increased. The overall AO activity in chicken liver was low compared to its hepatic FMO or CYP450 reported previously. Since FMO and AO activities are age-dependent in chicken livers, the impact of age on endogenous and exogenous metabolism by hepatic FMO and AO should be considered.

CITATION

Hu SX (2017) Age-Dependent Change of Hepatic Flavin Containing Monooxygenase and Aldehyde Oxidase Activities in Chickens. J Vet Med Res 4(5): 1088.

KEYWORDS

•    Flavin containing monooxygenase
•    Aldehyde oxidase
•    Chicken
•    Age

ABBREVIATIONS

AO: Aldehyde Oxidase; BCA: Bicinchoninic Acid; CYP450: Cytochrome P450; FMO: Flavin Containing Monooxygenase; IC50: Half Maximal Inhibitory Concentration; LC/MS: Liquid Chromatography Mass Spectrometry; MRM: Multiple Reaction Monitoring; NADPH: Reduced β-nicotinamide Adenine Dinucleotide 2′-Phosphate; RCF: Relative Centrifuge Force; SULT: Sulfotransferase; UGT: Uridine Diphosphate Glucuronosyl Transferase

 

INTRODUCTION

Hepatic metabolizing enzymes play important roles in the metabolism of endogenous and exogenous molecules in animals and humans. Flavin containing monooxygenases (FMO) and aldehyde oxidases (AO) are two important groups of non-cytochrome P450 (CYP450) oxygenases and have unique characteristics in drug metabolism. Microsomal FMO catalyze NADPH-dependent oxygenation of soft nucleophilic heteroatoms, such as N or S, of compounds. FMO often produce distinct metabolites although both CYP450 and FMO can oxidize many of the same substrates. FMO are not induced and rarely inhibited. They generally convert lipophilic nucleophiles to more polar and readily excreted metabolites with reduced pharmacological activity [1]. AO are cytosolic enzymes and not NADPH dependent. AO act on a wide range of substrates with different chemical structures and functionalities, especially nitrogen-containing heterocyclic compounds such as pyridines, diazines, benzimidazole, purines and a variety of other fused heteroaromatic compounds [2,3].

Different FMO and AO isoforms have been identified among different species. FMO3 is the only FMO isoform currently identified in chicken [4]. Most attention on FMO3 in chickens is on metabolism of trimethylamine in laying hens. Trimethylamine results in fishy taint in eggs [5-7]. An understanding of the development of FMO3 in chicken livers is limited. AO1 is the only AO isoform identified and isolated from chicken [8]. Unlike humans and rodents, whose AO1 is predominantly expressed in the livers and lungs, the highest expression of AO1 in chicken is in the kidneys and heart [9]. Information regarding AO1 in chicken livers is limited.

The purpose of this investigation was to assess age-dependent developmental patterns of hepatic FMO and AO activities in chickens. FMO activity in chicken liver microsomes and AO activity in chicken liver cytosols from the livers of 5-ages of chickens, 1, 7, 14, 28 and 56 days were measured using selective substrates of FMO and AO.

MATERIALS AND METHODS

Chemicals

O6 -benzylguanine, benzydamine hydrochloride, benzydamine N-oxide hydrogen maleate, raloxifene hydrochloride, estradiol, chlorpromazine hydrochloride, clomiphene citrate, tamoxifen citrate, methimazole and β-nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate (NADPH) were purchased from Sigma-Aldrich (St. Louis, MO). 8-oxo-benzylguanine was bought from Toronto Research Chemicals (Canada).

Animal work

All animal work was conducted under the oversight of the Institutional Animal Care and Use Committee (IACUC), and according to local, state, and national regulations. Ross 708 broiler raising and husbandry conditions were conducted as described previously [10]. Male chickens were randomly selected for liver collection at days 1, 7, 14, 28 and 56 post-hatch. The numbers of male chickens selected at each sampling day were 64, 32, 16, 8 and 6, respectively, considering chicken liver weights for preparation. Liver collection was performed as described previously [10].

Liver microsomes and cytosol preparation

Male chicken livers collected at days 1, 7, 14, 28 and 56 were processed for liver microsomes and cytosols. Every eight livers collected on day 1 and every two livers collected on day 7 were randomly combined for processing due to liver weights. Chicken livers collected on other days were processed individually. Three sets of liver samples collected on the aforementioned days were processed to liver powder using a SPEXSamplePrep 6870 Freezer/Mill (Metuchen, NJ) as described previously [10].

Weighed chicken liver powder was then prepared to liver microsomes and cytosols as described previously [10].

Protein content measurement

Protein content in chicken microsomes and cytosols was measured using the Thermo Scientific Pierce BCA protein assay kit (Rockford, IL) and a BMG Labtech PHERA star FS plate reader (Ortenberg, Germany) described previously [10].

FMO activity measurement

FMO activity was determined by N-oxidation of benzydamine in chicken liver microsomes. Chicken liver microsomes (0.1 mg protein/mL) were pre-incubated with NADPH (final concentration 1mM) in pH 7.4 phosphate (100 mM with10 µM MgCl2 ) buffer in 96-well plates at 41o C for 3 min. The reaction was initiated by adding a series of concentrations of benzydamine (0, 2.5, 5, 10, 25, 50, 100 and 200 µM). Organic solvents (methanol or acetonitrile) were 0.5% in all incubations. The reactions were terminated with cold acetonitrile after 10 min. The mixtures were centrifuged at 4o C and 20,000 RCF in an Eppendorf 5417R centrifuge (Hauppauge, NY) for 20 min. The supernatants were analyzed for the formation of benzydamine N-oxide.

FMO activity deactivation and inhibition

Thermo-deactivation of FMO activity was measured by preincubating chicken liver microsomes (0.1 mg protein/mL) in pH 7.4 phosphate (100 mM with10 µM MgCl2 ) without NADPH at 49o C for 5 min. The mixtures were allowed to cool down in ice. Then, NADPH was added and benzydamineN-oxidation was performed using the above procedure.

Chemical inhibition of FMO activity was only performed in the liver microsomes from the chickens of 1-day, 14-days and 56- days old groups. Chicken liver microsomes (0.1 mg protein/mL) were pre-incubated with NADPH (final concentration 1mM) and 50 µM Clomiphene or 100 µM Tamoxifen or 200 µM Methimazole in pH 7.4 phosphate (100 mM with10 µM MgCl2 ) buffer in 96-well plates at 41o C for 3 min. Then 200 µM benzydamine was added to start reactions as described above. The inhibition was demonstrated by percent reduction of formed benzydamine N-oxide relative to the reaction without the inhibitors.

AO activity measurement

AO activity was determined by oxidation of O6 -benzylguanine in chicken liver cytosol. A series of concentrations (0, 2.5, 5, 10, 25, 50, 100 and 250 µM) of O6 -benzylguanine were pre-incubated in pH 7.4 phosphate (100 mM with10 µM MgCl2 ) buffer at 41o C for 3 min. The metabolizing reaction was initiated by adding chicken liver cytosols (0.1 mg protein/mL). The reactions were terminated after 10 min with cold acetonitrile. The mixtures were centrifuged at 4 o C and 20,000 RCF in an Eppendorf 5417R centrifuge for 20 min. The supernatants were then analyzed for the formation of 8-oxobenzylguanine.

Aldehyde oxidase activity inhibition

Chemical inhibition of AO activity was only performed in liver cytosols from the chickens of the 56-days old group. O6 - benzylguanine (250 µM ) was pre-incubated in pH 7.4 phosphate (100 mM with10 µM MgCl2 ) buffer with 100 µM raloxifene or 200 µM menadione or 200 µM allopurinol in 96-well plates at 41o C for 3 min. The reaction was initiated by adding the chicken liver cytosols (0.1 mg protein/mL). Then the reactions were terminated as above for analysis of 8-oxobenzylguanine formation.

Liquid chromatography-mass spectrometry (LC/MS) analysis

Benzydamine N-oxide and 8-oxobenzylguanine were analyzed by an LC/MS system consisting of a Waters AcquityUPLC and an Applied Biosystem API 4000 Q trap mass spectrometer. Separation was accomplished using an AcquityUPLCBEHC18 column (1.7 μm, 2.1 x 50 mm) eluted with a 2 min gradient using acetonitrile and water with 0.1 percent formic acid as mobile phases at a flow rate of 0.4 mL/min and a column temperature of 40 o C. The MRM transitions of benzydamine N-oxide and 8-oxobenzylguanine were from m/z 326 to 265 and 258 to 91, respectively, using positive electrospray ionization mode on the mass spectrometer. The formed metabolites were quantified with calibration standards from 0 to 5000 nM.

Data processing

The apparent Michaelis-Menten kinetic parameters, Vmax and Km, were obtained from a nonlinear regression fitting of metabolite formation rates against incubation concentrations of benzydamine or O6 -benzylguanine using SigmaPlot v 9.0 (Systat Software, Inc., San Jose, CA). FMO and AO activities were expressed using the intrinsic clearance, the ratio of enzymatic parameters Vmax/Km with the unit µL/min/mg protein.

 

RESULTS

FMO activity was measured by N-oxidation of benzydamine in chicken liver microsomes. The oxidation was illustrated in an age-dependent manner in chicken livers (Figure 1). The hepatic activity was 71.0 ± 1.6 µL/min/mgin chickens immediately post hatch, rapidly declined to its lowest (9.8 ± 2.5 µL/min/mg) at age of 14-days, and then gradually increased to 43.4 ± 8.3 µL/min/ mg at the age of 56-days.

Pre-heating for 5 min at 49 o C reduced FMO activity to 74, 51, 0, 49 and 68 percent in liver microsomes of chickens at ages of 1, 7, 14, 28 and 56-days. This thermal deactivation was more effective when FMO activity was high but limited when the activity was low (Figure 1). FMO selective inhibitors, clomiphene, tamoxifen and methimazole at their given concentrations demonstrated equivalent or higher inhibition on benzydamine N-oxidation than pre-heating in chicken liver microsomes (Figure 2), especially in the liver microsomes with the lowest FMO activity at age of 14-days. Methimazole at 200 µM showed the most effective inhibition on chicken hepatic FMO activity in all tested ages.

Hepatic AO activity in chickens was monitored using O6 - benzylguanine oxidation. Age had an impact on AO activity in chicken livers (Figure 3). The lowest hepatic activity was detected at the age immediate post hatch and then increased with age of chickens. Although hepatic AO activity was low compared to FMO in chicken livers across the ages, it was obviously detectable.

Inhibition of O6 -benzylguanine oxidation was evaluated with AO inhibitors, raloxifene and menadione, and a xanthine oxidase inhibitor allopurinol in the chicken liver cytosols of age 56-days. Raloxifene at 100µM resulted in about 40 percent inhibition of this oxidation. But menadione and allopurinol demonstrated minimal or no inhibition at all (Figure 4).

The apparent Km values of benzydamine N-oxidation and O6 - benzylguanine oxidation in chicken livers are demonstrated in Table 1.

DISCUSSION

N-oxidation on the tertiary nitrogen of benzydamine is a distinct reaction of FMO. This metabolic reaction has been used to assess hepatic FMO activities in a variety of species, including livestock such as pig and cattle [11-16]. O6 -Benzylguanine can be metabolized to 8-oxo-benzylguanine by CYP450 and AO. This metabolism occurs in liver cytosols predominantly by AO in the absence of NADPH [17,18].

Age has significant impact on hepatic FMO activity in chickens. The high FMO activity immediately post hatch and then rapid reduction afterwards are similar to the activities of CYP450 and phase II conjugate enzymes (UGT and SULT) in chickens [10,19]. This unique feature is quite different from rodents or mammals. The early embryonic development of chicken livers may play important roles on such phenomenon [10]. After the activity reduced to the lowest, it then gradually increased with age. The husbandry conditions and diets seem no impact on this phenomenon [10]. Chicken hepatic FMO is crucial in detoxification of natural toxicants, such as pyrrolizidine alkaloids produced by a variety of plant species. FMO has more contributions than CYP450 in metabolism of such natural toxicants in chickens [20]. In laying hens, FMO has played a critical role in eliminating trimethylamine by N-oxidation to prevent fishy-eggs due to accumulation of this molecule in egg yolks [5,21,22]. Since hepatic FMO activity changes with age, the FMO dependent metabolism of endogenous and exogenous compounds should be impacted by age of chickens.

Inhibition of N-oxidation by thermal deactivation at absence of NADPH is a distinct procedure to distinguish CYP450 and FMO activities in liver microsomes [1]. Effectiveness of this thermal deactivation is at least partially FMO activity-dependent as demonstrated in this study. A similar phenomenon has been observed in a species comparison. Pre-heating at 45 o C for 5 min eliminates almost 100 percent of benzydamine N-oxidation in dog and rat liver microsomes but only 60 to 80 percent of the activity in human and monkey liver microsomes while the intrinsic clearance of benzydamine through N-oxidation is 1700, 280, 9.2 and 11 µL/min/mg in dog, rat, human and monkey liver microsomes, respectively [16]. FMO enzymes may be less thermal labile when their activity or density is low at endoplasmic reticulum of liver cells. Chicken hepatic FMO may be relatively more thermal stable since the average body temperature of chickens is 41 o C which is higher than mammals and rodents.

Chemical inhibition is more effective to chicken hepatic FMO. Methimazole, tamoxifen and clomiphene are FMO inhibitors. Methimazoleat 200 µM is more competitive than tamoxifen at 100 µM and clomiphene at 50 µM in inhibition of human FMO3[23], which is consistent in FMO inhibition in chicken liver microsomes of this study. Selectivity of different FMO inhibitors is species or FMO isoform dependent. For example, the lack of inhibition on benzydamine N-oxidation by methimazoleto 500 µM has been observed in porcine liver microsomes [14] in which FMO1 and FMO3 are both expressed [15]. In this study methimazoleat 200 µM was most effective in the inhibition of chicken hepatic FMO although the percent inhibition was somehow FMO activitydependent.

Hepatic AO levels in chicken livers were low but detectable across ages from day 1 to 56 using O6 -benzylguanine oxidation. The lower AO activity immediately post hatch and its increase with age of chickens are different from the developmental patterns of other hepatic metabolizing enzymes in chickens [10,19]. This implies that chicken hepatic AO may only be developed near or after hatch. The low hepatic AO activity is consistent with the AO1 mRNA expression measurement in different tissues of chickens. AO1 mRNA has been detectable only in chicken kidneys and hearts but not in chicken livers using Northern blot, although the much more sensitive RT-PCR method highlights the transcript in other chicken organs, including the liver [9]. Hepatic AO activity in chickens is much lower than in rodents and most mammals [24]. However this enzyme still contributes to metabolism of endogenous molecules, such as vitamin A1 and A2 [25], or exogenous compounds, such as neonicotinoid insecticides [24] and coumarinrodenticides [26] in chicken livers. Chicken hepatic AO may also be involved in the metabolism of olaquindox, a antimicrobal feed additive in chicken feed [27].

Allopurinol is a standard xanthine oxidase inhibitor with reported IC50 values of 0.2 to 50 µM in a variety of in vitro assays [28]. Menadione is an AO inhibitor with an IC50 value 0.2 µM for human AO [29]. Menadione inhibits O6 -benzylguanine oxidation effectively in human liver cytosolic fractions but allopurinol does [17]. However it has been observed that menadione inhibits an AO mediated metabolism of bisdesoxyolaquindoxin rat and pig liver cytosols at 100 µM but not in chicken liver cytosol at all [27]. In this study, both menadione and allopurinol at 200 uM had limited or no inhibition on O6 -Benzylguanine oxidation. Raloxifene is a potent and highly selective uncompetitive AO inhibitor. Its Ki values are about 1 nM for several AO mediated metabolisms [29]. In human liver cytosol, raloxifene (50 µM) can inhibit AO oxidation to 100 percent [30]. In this study, O6 - Benzylguanine oxidation was only inhibited to 40 percent by raloxifene at 100 µM in chicken liver cytosols. This probably indicates the difference of selectivity of that AO inhibitors to O6 - benzylguanine oxidation in chickens and other species.

In summary, hepatic FMO and AO activities are age-dependent in chickens. High FMO activity at hatch followed by rapid reduction is similar to other metabolizing enzymes in chicken livers. The age pattern of hepatic AO activity is different from other metabolizing enzymes in chickens besides the overall low activity across ages. Age has an obvious impact on hepatic FMO and AO activities in chicken livers and the implications of those differences on the metabolism of endogenous and exogenous compounds should be further evaluated.

ACKNOWLEDGEMENTS

The study was supported and funded by Veterinary Medicine Research and Development, Zoetis, Inc. The author thanks Ms. Shu Situ, a 2011 summer intern for processing chicken liver subfractions.

REFERENCES

1. Cashman JR. Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem Biophys Res. Commun. 2005; 338: 599-604.

2. Garattini E, Terao M. The role of aldehyde oxidase in drug metabolism. Expert Opin Drug MetabToxicol. 2012; 8: 487-503.

3. Sanoh S, Tayama Y, Sugihara K, Kitamura S, Ohta S. Significance of aldehyde oxidase during drug development: effects on drug metabolism, pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet. 2015; 30: 52-63.

4. Furnes B, Feng J, Sommer SS, Schlenk D. Identification of novel variants of the flavin-containing monoxygenase gene family in African Americans. Drug Metab Dispos. 2003; 31: 187-193.

5. Honkatukia M, Reese K, Preisinger R, Tuiskula-Haavisto M, Weigend S, Roito J, et al. Fishy taint in chicken eggs is associated with a substitution with a conserved motif of the FMO3 gene. Genomics. 2005; 86: 225-232.

6. Hamid MA, Wang X, Zhao X. Genotyping of Flavin-containing mono-oxygenase 3 (FMO3) gene by polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) and mismatch amplification mutation assay (MAMA-PCR) in chickens. Afr J Biotechnol. 2012; 11: 1823-1828.

7. Bao Y, Dong X, Tong J, Zhai Q. Formation mechanism and influencing factors of fishy-tainted eggs. Chinese J Anim Nutr. 2013; 25: 1412- 1417.

8. Garattini E, Fratelli M, Terao M. Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci. 2008; 65: 1019-1048.

9. Terao M, Kurosaki M, Barzago MM, Varasano E, Boldetti A, Bastone A, et al. Avian and canine aldehyde oxidases. Novel insights into the biology and evolution of molybdo-flavoenzymes. J Biol Chem. 2006; 281: 19748-19761.

10. Hu SX. Effect of age on hepatic cytochrome P450 of Ross 798 broiler chickens. Poult Sci. 2013; 92: 1283-1291.

11. Kawaji A, Ohara K, Takabatake E. An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation. Anal Biochem. 1993; 214: 409-412.

12. Störmer E, Roots I, Brockmöller J. Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol. 2000; 50: 553-561.

13. Santi A, Anfossi P, ColdhamNG, Capolongo F, Sauer MJ, Montesissa C. Biotransformation of benzydamine by microsomes and precision-cut slices prepared from cattle liver. Xenobiotica. 2002; 32: 73-86.

14. Capolongo F, Santi A, Anfossi P, Montesiss C. Benzydamine as a useful substrate of hepatic Flavin-containing monooxygenase activity in veterinary species. J Vet PharmacolTher. 2010; 33: 341-346.

15. Yamazaki M, Shimizu M, Uno Y, Yamazaki H. Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochem Pharmacol. 2014; 90: 159-165.

16. Taniguchi-Takizawa T, Shimizu M, Kume T, Yamazaki H. Benzydamine N-oxygenation as an index for Flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys and humans. Drug Metab Pharmacokinet. 2015; 30: 64-69.

17. Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME. Human liver oxidative metabolism of O6 -benzylguanine. Biochem Pharmacol. 1995; 50: 1385-1389.

18. Roy SK, Gupta E, Dolan ME. Pharmacokinetics of O6 -benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos. 1995; 23: 1394-1399.

19. Hu SX. Age-related change of hepatic uridine diphosphate glucuronosyltransferase and sulfotransferase activities in male chickens and pigs. J Vet Pharmacol Ther. 2017; 40: 270-278.

20. Huan JY, Miranda CL, Buhler DR, Cheeke PR. Species differences in the hepatic microsomal enzyme metabolism of the pyrrolizidine alkaloids. Toxicol Lett. 1998; 99: 127-137.

21. Kretzschmar K, Dãnicke S, Schmutz M, Preisinger R, Weigend S. Interactions of Flavin containing monooxygenase 3(FMO3) genotype and feeding of choline and rapeseed cake on the trimethylamine (TMA) content in egg yolks of laying hens. Arch Anim Nutr. 2009; 63: 173-187.

22. Wang J, Wu SG, Zhang HJ, Yue HY, Xu L, Ji F, et al. Trimethylamine deposition in the egg yolk from laying hens with different FMO3 genotypes. Poult Sci. 2013; 92: 746-752.

23. Catucci G, Polignano I, Cusumano D, Medana C, Gilardi G, SadeghiSJ. Identification of human flavin-containing monooxygenase 3 substrates by a colorimetric screening assay. Anal Biochem. 2017, 522: 46-52.

24. Dick RA, Kanne DB, Casida JE. Identification of aldehyde oxidase as the neonicotinoid nitroreductase. Chem ResToxicol. 2005; 18: 317-323.

25. Lakshmanan MR, Vaidyanathan CS, Cama HR. Oxidation of vitamin A1 and aldehyde and vitamin A2 aldehyde to corresponding acids by aldehyde oxidase from different species. Biochem J. 1964; 90: 569- 573.

26. Saengtienchai A, Ikenaka Y, Watanabe K, Ishida T, Ishizuka M. Comparative metabolism of warfarin in rats and chickens. Poult Sci. 2011; 90: 2775-2781.

27. Liu ZY, Chen DM, Huang LL, Tao YF, Yao M, Yuan ZH. In vitro biotransformation and investigation of metabolic enzymes possibly responsible for the metabolism of bisdesoxyolaquindox in the liver fractions of rats, chicken, and pigs. Toxicology. 2011; 279: 155-166.

28. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006; 58: 87-114.

29. Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos. 2004; 32: 89-97.

30. Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J ClinPharmacol. 2004; 44: 7-19.

Hu SX (2017) Age-Dependent Change of Hepatic Flavin Containing Monooxygenase and Aldehyde Oxidase Activities in Chickens. J Vet Med Res 4(5): 1088.

Received : 29 May 2017
Accepted : 16 Jun 2017
Published : 19 Jun 2017
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X